Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio
Executive Summary
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
You may also be interested in...
Syncona Buys Out Ailing Gene Therapy Company Freeline
Syncona has stepped in to save Freeline and give it more time to prove the value of FLT201, its early-stage Gaucher’s disease gene therapy.
Novartis Casts Nets Globally To Snap Up Best Assets
The Swiss major’s business development chief Susanne Kreutz tells Scrip that geography is no barrier for her team in the search for promising licensing deals or bolt-on acquisitions.
Ironwood Paying $1bn For VectivBio To Extend Its GI Franchise Beyond Linzess
Ironwood said it believes VectivBio’s once-weekly GLP-2 analog apraglutide is differentiated from Takeda’s once-daily Gattex in short bowel syndrome and could generate $1bn in peak sales.